AMRUTANJAN
Amrutanjan Health Care share price & financials
- Price
- ₹538.2
- Market cap
- ₹1.4k Cr
- Sector
- Healthcare
What Amrutanjan Health Care Limited does
Amrutanjan Health Care manufactures and markets over-the-counter pain-relief and congestion products, women's hygiene and personal-care items, and rehydration/ORS beverages, distributed nationally through a stockist-distributor network into chemists, general trade and modern trade. Its OTC portfolio (Amrutanjan balms, roll-ons, sprays and patches for pain, and the Relief brand for congestion) is produced at plants in Alathur, Kancheepuram district, Tamil Nadu and Uppal, Hyderabad, Telangana. The Comfy brand of sanitary napkins, along with newly added personal-care lines such as razors and antiseptic plaster, and the Electro+/Enerlyte rehydration drinks and WHO-approved ORS powders (made at a dedicated beverage plant in Aranvoyal village, Tiruvallur district, Tamil Nadu) round out the portfolio. The company also runs an in-house QA/R&D function supporting formulation and product development.
Segments
- OTC Products
- Women's Hygiene & Personal Care
- Beverages
- Manufacturing units
- 3 (Alathur, Tamil Nadu; Uppal, Telangana - OTC; Aranvoyal, Tamil Nadu - Beverages)
- Distributors
- 1,656
- Outlet reach (Rubefacient segment)
- 1.11 Mn outlets
- Employees
- 631
- Suppliers
- 914
- Core power brands
- 4 (Amrutanjan, Relief, Comfy, Enerlyte/Electro+)
Quarterly results
Q1 FY27: revenue up 9.5%, net profit down 47.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 110 | 123 | 135 | 94 | 118 +7% | 141 +15% | 150 +11% | 103 +9% |
| EBITDA | 14 | 23 | 18 | 8 | 17 +21% | 25 +8% | 26 +44% | 6 −26% |
| Net profit | 12 | 19 | 15 | 8 | 14 +18% | 19 +1% | 16 +7% | 4 −47% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −35.0% 1Y
1Y: ₹755.35 on 10 Sept 2025 → ₹490.95. High ₹765 (17 Sept 2025), low ₹488.25 (18 Aug 2026).
Financials, as filed
Revenue grew 9.8% a year over 3 years, FY23 to FY26. Operating margin widened to 15.1%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹380 Cr | ₹421 Cr | ₹452 Cr | ₹503 Cr |
| Operating profit | ₹44 Cr | ₹52 Cr | ₹58 Cr | ₹76 Cr |
| Operating margin | 11.7% | 12.3% | 12.9% | 15.1% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹5 Cr | ₹6 Cr | ₹7 Cr | ₹6 Cr |
| Net profit | ₹41 Cr | ₹45 Cr | ₹51 Cr | ₹58 Cr |
| Net margin | 10.7% | 10.7% | 11.3% | 11.5% |
| Cash from operations | ₹20 Cr | ₹28 Cr | ₹51 Cr | ₹36 Cr |
| Free cash flow | ₹11 Cr | ₹21 Cr | ₹15 Cr | ₹-19 Cr |
| ROCE | 19.0% | 21.0% | 22.0% | 25.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
| Reserves | ₹213 Cr | ₹262 Cr | ₹288 Cr | ₹286 Cr | ₹339 Cr | ₹367 Cr |
| Borrowings | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Other liabilities | ₹57 Cr | ₹84 Cr | ₹70 Cr | ₹77 Cr | ₹88 Cr | ₹137 Cr |
| Total liabilities | ₹274 Cr | ₹350 Cr | ₹362 Cr | ₹367 Cr | ₹432 Cr | ₹509 Cr |
| Fixed assets | ₹23 Cr | ₹28 Cr | ₹49 Cr | ₹50 Cr | ₹49 Cr | ₹51 Cr |
| Capital work in progress | ₹2 Cr | ₹17 Cr | ₹1 Cr | ₹2 Cr | ₹26 Cr | ₹106 Cr |
| Investments | ₹18 Cr | ₹13 Cr | ₹5 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr |
| Other assets | ₹232 Cr | ₹291 Cr | ₹307 Cr | ₹315 Cr | ₹357 Cr | ₹349 Cr |
| Total assets | ₹274 Cr | ₹350 Cr | ₹362 Cr | ₹367 Cr | ₹432 Cr | ₹509 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, DIIs trimmed −0.41 pp while the public added +0.38 pp. The shareholder count shrank 9% to 45,135.
- Promoters
- 46.5%
- FIIs
- 2.4%
- DIIs
- 12.3%
- Public
- 38.7%
- Others
- 0.0%
Since Jun 2025
- DIIs −0.41 pp
- Public +0.38 pp
- FIIs +0.03 pp
How it drifted, 12 quarters
Over this window DIIs went from 7.1% to 12.3% — +5.2 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 50.6%, FIIs 0.8%, DIIs 7.1%, Public 41.4%, Others 0.2%.Dec '23: Promoters 50.6%, FIIs 0.8%, DIIs 7.2%, Public 41.2%, Others 0.2%.Mar '24: Promoters 50.6%, FIIs 1.4%, DIIs 7.3%, Public 40.7%, Others 0.1%.Jun '24: Promoters 50.6%, FIIs 1.6%, DIIs 7.3%, Public 40.5%, Others 0.1%.Sep '24: Promoters 46.5%, FIIs 2.3%, DIIs 10.6%, Public 40.5%, Others 0.0%.Dec '24: Promoters 46.5%, FIIs 2.3%, DIIs 11.1%, Public 40.0%, Others 0.0%.Mar '25: Promoters 46.5%, FIIs 2.3%, DIIs 11.4%, Public 39.8%, Others 0.0%.Jun '25: Promoters 46.5%, FIIs 2.4%, DIIs 12.7%, Public 38.3%, Others 0.0%.Sep '25: Promoters 46.5%, FIIs 2.4%, DIIs 12.9%, Public 38.2%, Others 0.0%.Dec '25: Promoters 46.5%, FIIs 2.3%, DIIs 13.0%, Public 38.2%, Others 0.0%.Mar '26: Promoters 46.5%, FIIs 2.2%, DIIs 12.7%, Public 38.6%, Others 0.0%.Jun '26: Promoters 46.5%, FIIs 2.4%, DIIs 12.3%, Public 38.7%, Others 0.0%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Ramaa Prabhakar Arikirevula +1.72 pp 4.74% held
The same filing shows 2 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Amrutanjan Health Care Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Goodhealth Holdings Private Limited | 20.15% | unchanged |
| Sambhuprasad Sivalenka | 10.34% | unchanged |
| Ramaa Prabhakar Arikirevula | 4.74% | +1.72 pp |
| DSP Small Cap Fund Mutual fund | 3.80% | −1.10 pp |
| Carnelian Bharat Amritkaal Fund AIF | 2.98% | unchanged |
| Ramalingam Ganti | 2.53% | unchanged |
| Amulya Kamakshi Priya Arikirevula | 2.13% | unchanged |
| ICICI Prudential FMCG Fund Mutual fund | 2.01% | −0.10 pp |
| Investor Education and Protection Fund (IEPF) | 1.50% | unchanged |
| Dipak Kanayalal Shah | 1.12% | unchanged |
| Carnelian Structural Shift Fund AIF | 1.09% | unchanged |
| Ramaa Prabhakar Arikirevula - 2 | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
ExpensiveTo justify its price of ₹491, this stock must grow earnings at 19% every year for 7 years. Our analysis caps realistic growth at ~14%. At that growth it is worth ₹372 — downside of 24%.
- Growth the price implies
- 19.0% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 12.5% a year
- net profit, FY23–FY26 · EPS 13.7%
- The gap
- 0.1 pp
- -24% downside if it only repeats history
Learn to analyse Amrutanjan Health Care Limited
Guides on how to read this kind of business and the numbers that matter.